| abstract |
The present invention provides a method for determining whether a compound is capable of inhibiting the interaction of a peptide with receptor for advanced glycation end product (RAGE), which comprises: (a) admixing: (i) the peptide, wherein amino groups of the peptide are inactivated by derivitization, (ii) RAGE or a fragment thereof, and (iii) the compound; (b) determining the amount of the peptide bound to RAGE or the fragment thereof, and (c) comparing the amount of bound peptide determined in step (b) with the amount determined when the peptide is admixed with RAGE or a fragment thereof in the absence of the compound, thereby determining whether the compound is capable of inhibiting the interaction of the peptide with RAGE or a fragment thereof, wherein a reduction in the amount of binding in the presence of the compound indicates that the compound is capable of inhibiting the interaction. The present invention also provides a method for inhibiting the interaction of an advanced glycation endproduct (AGE) with a receptor for advanced glycation endproduct (RAGE) in a subject which comprises administering to the subject a pharmaceutically acceptable amount of the compound identified in aforementioned screening method effective to inhibit the interaction between the AGE and the RAGE in the subject. The present invention also provides for a compound identified by the screening method and which is useful for the treatment of diabetes in a subject. |